english.prescrire.org > Spotlight > 100 most recent > Sparsentan (Filspari°) in immunoglobulin A nephropathy

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Sparsentan (Filspari°) in immunoglobulin A nephropathy

 Marketing Authorisations  Sparsentan has been authorised in the European Union for use in adult patients with primary immunoglobulin A nephropathy with proteinuria. In this situation, does sparsentan slow disease progression and delay the onset of end-stage kidney disease? And what are its adverse effects?  
Full article available for download by subscribers

 ©Prescrire 1 June 2026

Source: "Sparsentan (Filspari°) in immunoglobulin A nephropathy" Prescrire Int 2026; 35 (282): 145-147. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:
 
"Finerenone (Kerendia°)
in chronic kidney disease
with albuminuria associated
with type 2 diabetes. High
incidence of hyperkalaemia,
and slim renal benefits"
Prescrire Int 2024;
33 (263): 229-232. 
Subscribers only